Subacromial-subdeltoid bursitis following COVID-19 vaccination: a case of shoulder injury related to vaccine administration (SIRVA)

Tatiane Cantarelli Rodrigues1 · Pedro Filgueiras Hidalgo2,3 · Abdalla Youssef Skaf1,4 · Aline Serfaty5,6

Received: 23 March 2021 / Revised: 25 April 2021 / Accepted: 26 April 2021 / Published online: 4 May 2021
© ISS 2021

Abstract
Vaccination injection site adverse reactions are usually mild and transient, and post-vaccination musculoskeletal symptoms, such as myalgia and arthralgia, are very common. Shoulder injury related to vaccine administration (SIRVA), defined as shoulder pain and limited range of motion occurring after the administration of a vaccine intended for intramuscular administration in the upper arm, is a well-established condition in the medical literature, yet underreported. In such cases, subacromial-subdeltoid bursitis may occur, leading to shoulder dysfunction and ongoing pain. Millions of doses of vaccines for the prevention of COVID-19 have been administered to adults worldwide during the pandemic. We report a case of subacromial-subdeltoid bursitis after COVID-19 vaccination, related to the unintentional injection of vaccine solution into the bursa resulting in a robust immune-mediated inflammatory reaction.

Keywords COVID-19 · SIRVA · Bursitis · Vaccine · Shoulder · MRI · Ultrasound

Introduction
Vaccination injection site adverse reactions are common, and symptoms are usually mild and transient [1–3], with pain, swelling, and redness at the site of injection being the most common clinical findings [3, 4]. Cases of shoulder injury related to vaccine administration (SIRVA), defined as shoulder pain and limited range of motion occurring after the administration of a vaccine intended for intramuscular administration in the upper arm, have been reported in the medical literature [2, 3, 5–8], and influenza is the most frequently vaccine reported [1, 3, 9, 10]. Although subacromial-subdeltoid bursitis is a common health problem with a prevalence of approximately 1% in the general US population [11], its occurrence within the context of SIRVA is still underreported in the literature.

The relationship between vaccine injection into synovial tissue and inflammation of the structures underlying the deltoid muscle has been well established [3–9]. In this setting, bursitis, adhesive capsulitis, and glenohumeral synovitis may occur [3–9], with potential need for medical assistance due to severe prolonged pain and joint mobility restriction [1, 5]. In the past 2 years, much has been studied about the multi-systemic involvement of COVID-19. However, potential adverse effects related to global COVID-19 vaccination still need to be further explored.

To our knowledge, this is the first case reported of post-vaccination subacromial-subdeltoid bursitis after a COVID-19 vaccination due to the unintentional injection of vaccine solution into the bursa, resulting into a robust immune-mediated inflammatory reaction. Raising awareness of this
underreported potential complication is crucial, as millions of people receive the injection with the ongoing roll-out of COVID-19 vaccination programs. The large number of vaccine doses administered daily [12] can lead to a significant increase in workload and rushed procedures, and as a consequence, the risk of inappropriately injected vaccines can also rise.

Case report

A 61-year-old woman presenting with excruciating pain and tenderness at the injection site in her right shoulder within 30 min after receiving her first shot of COVID-19 vaccine (Oxford-AstraZeneca, Serum Institute of India). She voiced concern about vaccine administration, specifically that the injection had been administered “too high” in the arm. Informed consent was obtained from the subject described in this report.

Photographs of the patient while receiving the vaccine were taken and confirmation of the incorrect technique used was noticed. The injection was administered at the level of two fingerbreadths of the lateral border of the acromion, which is considered higher than the recommendation (Fig. 1).

Initial treatment included ice pack, topical diclofenac cream, and a combination of caffeine, carisoprodol, sodium diclofenac, and paracetamol for 5 days from the vaccine injection.

Eight weeks after the vaccination, the patient was still experiencing persistent pain in the right shoulder and reduced range of motion with inability to perform daily activities. Upon physical examination, there was mild swelling of the upper arm and localized shoulder tenderness around the top of the humeral head and deltoid. Active and passive ranges of motion were evaluated through orthopedic maneuvers. The strength of the rotator cuff muscles and the normal passive range of motion were preserved. The active range of motion in the shoulder was limited with active painful arc (45° of abduction, 20° of extension, 45° of flexion). Neer’s, Hawkins’, Yocum’s, and O’Brien’s tests were positive, while Jobe’s and Patte’s tests were negative. Gerber’s test was not performed due to pain complaints. Physical neurovascular exam was normal.

Routine X-rays of the shoulder were performed and did not provide helpful diagnostic information (Fig. 2a). Shoulder MRI and ultrasound 8 weeks after vaccination supported a diagnosis of subacromial-subdeltoid bursitis and rotator cuff tendinopathy (Fig. 2b-f). The fluid-filled subacromial-subdeltoid bursa was greater than is commonly seen for overuse bursitis caused by mechanical stress. The correlation with hypertrophic synovial tissue raised the hypothesis of an underlying inflammatory cause.

The patient started prednisone oral treatment, vitamin D supplementation, and a physical therapy regimen to

Fig. 1 Photograph of the patient receiving her first dose of the COVID-19 vaccine (Oxford-AstraZeneca, Serum Institute of India) in Brazil’s vaccination program into the upper third of the right deltoid muscle, which is considered higher than the recommended area (red circle)
preserve the range of motion, in an attempt at minimizing potential complications, such as adhesive capsulitis.

As past medical history, the patient had diagnosed hypothyroidism due to Hashimoto’s thyroiditis, also known as chronic lymphocytic thyroiditis, treated with sodium levothyroxine for 21 years. No medical history of inflammatory arthropathy or previous COVID-19 infection was reported.

Discussion

A diagnosis of shoulder injury related to vaccine administration (SIRVA) was made due to the rapid onset of pain after intramuscular vaccine administration in a patient with no prior history of chronic pain or inflammatory diseases in the affected shoulder combined with findings consistent with a local immune-mediated inflammatory reaction. The key to recognizing SIRVA is that the pain usually begins within 48 h of vaccine administration, which may persist for months. Symptoms include associated weakness and impaired mobility, without improvement with over-the-counter analgesics [5].

Millions of doses of vaccines for the prevention of coronavirus disease 2019 have been administered to adults around the world during the COVID-19 pandemic [12]. Immunization using the COVID-19 vaccine AstraZeneca of individuals 18 years of age and older has been done since emergency use authorization for the shot on December 30, 2020, in the UK by the UK Medicines and Healthcare products Regulatory Agency (MHRA) [13]. AstraZeneca’s COVID-19 vaccine has been approved for emergency supply in Brazil on January 17, 2021, by the Brazilian Health Regulatory Agency (ANVISA) [14]. This vaccine should be given in two separate doses by an authorized vaccinator as an intramuscular injection only, preferably into the deltoid muscle [15].

One dose of COVID-19 vaccine contains $5 \times 10^{10}$ viral particles in 0.5 ml of solution. The active substance of COVID-19 vaccine AstraZeneca is a monovalent vaccine composed of a single recombinant, replication-deficient chimpanzee adenovirus (ChAdOx1) vector, that codes for the S glycoprotein of SARS-CoV-2 (ChAdOx1-S [recombinant]) [15].

The most common side effects reported with COVID-19 vaccine AstraZeneca, which may affect more than 1 in 10 people, were tenderness (63.7%) and pain (54.2%) at the injection site. Myalgia (44.0%) and arthralgia (26.4%) were common musculoskeletal side effects reported. During the clinical trials, a majority of adverse reactions reported were mild to moderate in nature and resolved within a few days, with some lasting for a week after vaccination. When compared to the first dose, adverse reactions reported after the second dose were milder and less frequent [15].

Our patient developed shoulder pain shortly after vaccination, possibly due to her vaccine being administered inadvertently higher than recommended (Fig. 3) [4, 7]. Atanasoff and colleagues, in a retrospective study about SIRVA, reported that in 93% of the cases, shoulder pain occurred less than 24 h after vaccination and immediately following injection in 54% [2].
This adverse reaction can also be caused when the injection is too deep, going through the muscle and into the bursa [4, 7, 8, 10]. Bodor and Montalvo found that the subdeltoid bursa extended from 3.0 to 6.0 cm beyond the lateral border of the acromion at a depth from 0.8 to 1.6 cm [7] which could be easily reached by the 2.5-cm (1-in.) needle used for the injection in our patient. Guidelines for proper administration, including explicit instruction to avoid the upper third of the deltoid, would help to reduce the risk of penetrating the bursa during vaccine injections [2]. Inappropriate technique could potentially reduce vaccine efficacy or increase the risk for local adverse reactions [4, 10].

The patient demonstrated reduced active range of motion and ongoing shoulder pain that lasted for at least 8 weeks after receiving her first shot of the COVID-19 vaccine. The most common findings upon examination of patients with SIRVA are an active painful arc, with the severity and duration of shoulder dysfunction varying among patients, which may ultimately last for years [2].

In cases in which severe local or systemic signs or symptoms are present and SIRVA is suspected, non-invasive imaging evaluation may be required immediately to rule out inflammatory conditions or infection and to determine the level and type of damage, especially when the symptoms persist and additional invasive procedures, such as steroid injections, might be considered [2].

When an individual is vaccinated, vaccine antigen–antibody interaction reaction caused by vaccination at the local site is expected to be transient and resolve as the antigen is cleared from the soft tissues over a period of several days [2]. However, in cases in which vaccine solution is inadvertently injected into the synovial space of the shoulder, pre-existing antibodies in the synovial tissues from previous infection or past-vaccination, may lead to a more prolonged inflammatory response [2].

Some authors [2] believe that this type of phenomenon is a result from injection of a vaccine antigen from which a person has previously been sensitized, rather than due to a specific vaccine. Although COVID-19 is a new infectious disease and the population is receiving COVID-19 vaccines for the first time, and although the patient had not
been previously directly exposed to the coronavirus, it is unlikely that an adult would not have had previous exposure to an adenovirus in the past, which is in fact a component of COVID-19 vaccine AstraZeneca.

The majority of patients may have persistent symptoms including pain and a limited range of motion [2, 5]. In many cases, resting and anti-inflammatory medications can lead to symptom resolution within a few weeks [3]; however, in some cases, an injection of a corticosteroid over time may be required[2, 5]. Surgical intervention can be performed in refractory cases [2, 10, 16].

The diagnosis of SIRVA should be considered in patients with established symptoms of shoulder pain following a vaccination. Vaccine administration in the upper third of the deltoid area can have long-lasting consequences unrelated to the specific vaccine administered. Awareness of the potential for inducing a prolonged immune-mediated inflammatory reaction if a vaccine antigen is injected into synovial tissue for inducing a prolonged immune-mediated inflammatory condition if the vaccine is administered properly. Mil-ship following a COVID19 vaccination. SIRVA is a preventable condition. Awareness of the potential risk of vaccines injected inappropriately can likewise increase. The diagnosis of SIRVA should be considered in patients with established symptoms of shoulder pain following a vaccination. Vaccine administration in the upper third of the deltoid area can have long-lasting consequences unrelated to the specific vaccine administered. Awareness of the potential for inducing a prolonged immune-mediated inflammatory reaction if a vaccine antigen is injected into synovial tissue for inducing a prolonged immune-mediated inflammatory condition if the vaccine is administered properly. Milship following a COVID19 vaccination. SIRVA is a preventable condition. Awareness of the potential risk of vaccines injected inappropriately can likewise increase.

SIRVA is well established in the medical literature [5, 17]; however, it is still an underreported condition. To our knowledge, this is the first case report with a causal relationship following a COVID19 vaccination. SIRVA is a preventable condition if the vaccine is administered properly. Millions of vaccines for COVID-19 are being administered daily to adults worldwide due to the pandemic; thus, the number of vaccines injected inappropriately can likewise increase. Shoulder injuries should be considered one of the potential adverse effects of the vaccination.

Declarations

Conflict of Interest The authors declare no competing interests.

References

1. Martín Arias LH, Sanz Fadrique R, Sáinz Gil M, Salgueiro-Vazquez ME. Risk of bursitis and other injuries and dysfunctions of the shoulder following vaccinations. Vaccine. 2017;35(37):4870–6. https://doi.org/10.1016/j.vaccine.2017.07.055.
2. Atanasoff S, Ryan T, Lightfoot R, Johann-Liang R. Shoulder injury related to vaccine administration (SIRVA). Vaccine. 2010;28(51):8049–52. https://doi.org/10.1016/j.vaccine.2010.10.005.
3. Batra S, Page B. Shoulder injury related to vaccine administration: case series of an emerging occupational health concern. Work-place Health Saf. 2021;69(2):68–72. https://doi.org/10.1177/2165079920925765.
4. Hexter AT, Gee E, Sandher D. Management of glenohumeral synovitis secondary to influenza vaccination. Shoulder Elbow. 2015;7(2):100–3. https://doi.org/10.1177/1758573214560258.
5. Bancsi A, Houle SKD, Grindrod KA. Getting it in the right spot: shoulder injury related to vaccine administration (SIRVA) and other injection site events. Can Fam J (Ott). 2018;151(5):295–9. https://doi.org/10.1177/1715163517790771.
6. Barnes MG, Ledford C, Hogan KA. “needling” problem: shoulder injury related to vaccine administration. J Am Board Fam Med. 2012;25(6):919–22. https://doi.org/10.3122/jabfm.2012.06.110334.
7. Bodor M, Montalvo E. Vaccination-related shoulder dysfunction. Vaccine. 2007;25(4):585–7. https://doi.org/10.1016/j.vaccine.2006.08.034.
8. Cross GB, Moghaddas J, Butterly J, Ayoub S, Korman TM. Don’t aim too high: avoiding shoulder injury related to vaccine administration. Aust Fam Physician. 2016;45(5):303–6.
9. Behrens RH, Patel V. Avoiding shoulder injury from intramuscular vaccines. Lancet. 2021;397(10273):471. https://doi.org/10.1016/S0140-6736(21)00192-6.
10. Hesse EM, Navarro RA, Daley MF, et al. Risk for subdeltoid bursitis after influenza vaccination: a population-based cohort study. Ann Intern Med. 2020;173(4):253–61. https://doi.org/10.7326/M19-3176.
11. Walker-Bone K, Palmer KT, Reading I, Coggon D, Cooper C. Prevalence and impact of musculoskeletal disorders of the upper limb in the general population. Arthritis Rheum. 2004;51(4):642–51. https://doi.org/10.1002/art.20535.
12. Ritchie H, Ortiz-Ospina E, Beltekian D, Mathieu E, et al. Our world in data: coronavirus (COVID-19) vaccinations . Accessed March 16th, 2021, 2021. https://ourworldindata.org/covid-vaccinations
13. 2021 Regulatory approval of COVID-19 Vaccine AstraZeneca (2020).
14. Relatorio: bases técnicas para decisão do uso emergencial, em caráter experimentar de vacinas contra a COVID 19 (2021).
15. Agency EM. COVID-19 vaccine AstraZeneca - product information as approved by the CHMP on 29 January 2021, pending endorsement by the European Commission. Accessed March 16th, 2021. https://www.ema.europa.eu/en/documents/product-information/approved-products/1289174420535
16. Bliddal H, Torp-Pedersen S, Falk-Riecke B, Bartels E. [Bursitis after vaccination in the shoulder region]. Ugeskr Laeger. Oct 2017;179(43).
17. Bancsi A, Houle SKD, Grindrod KA. Shoulder injury related to vaccine administration and other injection site events. Can Fam Physician. 01 2019;65(1):40–42.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.